Sanofi-Aventis to complete Zentiva acquisition

Sanofi-Aventis will hold a 94% stake in the Czech Republic's Zentiva when it completes its acquisition on March 11th. All the conditions put out by Sanofi-Aventis Europe, a subsidiary which is handling the deal, have been successfully fulfilled, it added.

Sanofi-Aventis will hold a 94% stake in the Czech Republic's Zentiva when it completes its acquisition on March 11th. All the conditions put out by Sanofi-Aventis Europe, a subsidiary which is handling the deal, have been successfully fulfilled, it added.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By 

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By 

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.